Literature DB >> 17938166

Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A).

Ann Meyer1, Kai Kossow, Andreas Gal, Chris Mühlhausen, Kurt Ullrich, Thomas Braulke, Nicole Muschol.   

Abstract

OBJECTIVE: Mucopolysaccharidosis types IIIA through IIID (Sanfilippo syndrome) are caused by deficiencies of enzymes involved in the degradation of heparan sulfate. The onset and severity of the disease are highly variable. The purpose of this study was to describe the natural course of mucopolysaccharidosis type IIIA in a large cohort of patients. PATIENTS AND METHODS: The natural course of mucopolysaccharidosis type IIIA was assessed in 71 patients by using a detailed questionnaire and a 4-point scoring system and compared with the course of the disease in 14 patients with mucopolysaccharidosis type IIIB and 4 patients with mucopolysaccharidosis type IIIC.
RESULTS: In the cohort of patients with mucopolysaccharidosis type IIIA, first symptoms of disease were observed, on average, at 7 months of age. Speech and motor development were delayed in 66.2% and 33.9% of patients, respectively. The median age at diagnosis was 4.5 years. The onset of regression in speech, motor, and cognitive function was observed at an average age of 3.3 years. The loss of all 3 of the assessed abilities was observed at an average age of 12.5 years. Speech was lost before motor and cognitive functions. In a small group of patients who were >12.5 years of age (9.9%), speech, motor, and cognitive skills were partially preserved up to a maximum age of 23.8 years.
CONCLUSIONS: To our knowledge, this is the first systematic and comprehensive study on the natural course of mucopolysaccharidosis type IIIA. The 4-point scoring system may be used to classify patients into groups with a rapid or slower course of the disease. This may have an important impact on parental counseling as well as therapeutic interventions.

Entities:  

Mesh:

Year:  2007        PMID: 17938166     DOI: 10.1542/peds.2007-0282

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  44 in total

1.  A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley
Journal:  J Pediatr       Date:  2016-01-16       Impact factor: 4.406

2.  Ataxia is the major neuropathological finding in arylsulfatase G-deficient mice: similarities and dissimilarities to Sanfilippo disease (mucopolysaccharidosis type III).

Authors:  Björn Kowalewski; Peter Heimann; Theresa Ortkras; Renate Lüllmann-Rauch; Tomo Sawada; Steven U Walkley; Thomas Dierks; Markus Damme
Journal:  Hum Mol Genet       Date:  2014-12-01       Impact factor: 6.150

3.  Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.

Authors:  Alexander Langford-Smith; Fiona L Wilkinson; Kia J Langford-Smith; Rebecca J Holley; Ana Sergijenko; Steven J Howe; William R Bennett; Simon A Jones; Je Wraith; Catherine Lr Merry; Robert F Wynn; Brian W Bigger
Journal:  Mol Ther       Date:  2012-05-01       Impact factor: 11.454

Review 4.  Clinical aspects of neuropathic lysosomal storage disorders.

Authors:  Laura Bannach Jardim; Maria Mercedes Villanueva; Carolina F Moura de Souza; Cristina B Oliveira Netto
Journal:  J Inherit Metab Dis       Date:  2010-05-21       Impact factor: 4.982

Review 5.  Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

Authors:  E M Cross; D J Hare
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

6.  Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).

Authors:  Sheena Grant; Elaine Cross; James Edmond Wraith; Simon Jones; Louise Mahon; Michelle Lomax; Brian Bigger; Dougal Hare
Journal:  J Inherit Metab Dis       Date:  2012-11-15       Impact factor: 4.982

7.  Methods of neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome.

Authors:  Kathleen A Delaney; Kyle R Rudser; Brianna D Yund; Chester B Whitley; Patrick A J Haslett; Elsa G Shapiro
Journal:  JIMD Rep       Date:  2013-11-05

8.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 9.  Sanfilippo syndrome: a mini-review.

Authors:  M J Valstar; G J G Ruijter; O P van Diggelen; B J Poorthuis; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

10.  Natural history of Sanfilippo syndrome type A.

Authors:  Dakota Buhrman; Kavita Thakkar; Michele Poe; Maria L Escolar
Journal:  J Inherit Metab Dis       Date:  2013-11-23       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.